IM Cannabis Q4 2024 Earnings Report

IM Cannabis EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$0.39
• Beat/Miss: Beat by +$0.16
• One Year Ago EPS: N/A

IM Cannabis Revenue Results

• Actual Revenue: $9.27 million
• Expected Revenue: $14.48 million
• Beat/Miss: Missed by -$5.21 million
• YoY Revenue Growth: N/A

IM Cannabis Announcement Details

• Quarter: Q4 2024
• Date: 3/31/2025
• Time: Before Market Opens
• Conference Call Date: Monday, March 31, 2025
• Conference Call Time: 9:00AM ET

IM Cannabis (NASDAQ:IMCC) Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards. IM Cannabis invests in ongoing scientific research and development to advance proprietary extraction techniques and novel dosage forms, with an emphasis on patient safety, reproducibility and therapeutic efficacy. These efforts support both internal clinical initiatives and potential collaborations with academic and pharmaceutical partners.

Since its founding in 2018, IM Cannabis has pursued domestic and international market expansion through supply agreements and export licenses. The company serves Israel’s growing medical cannabis patient base and has secured partnerships to facilitate exports to regulated markets, including Europe and Australia. IM Cannabis is led by an experienced management team with backgrounds in pharmaceutical development, agriculture technology and regulatory affairs, and trades on the Nasdaq Capital Market under the ticker IMCC.

IM Cannabis Q4 2024 Earnings Call Transcript

Key Takeaways

• Germany market acceleration: Since April 2024's partial legalization, Q4 German revenue surged 280%, with Germany accounting for 40% of H2 2024 total revenue versus 11% in 2023.
• Positive adjusted EBITDA: Q4 2024 delivered a €0.5 million adjusted EBITDA profit versus a €4.3 million loss in Q4 2023, and full-year adjusted EBITDA loss narrowed to €1.1 million from €8.0 million.
• Cost reduction: Operating expenses were cut by 17% in 2024 to $18.7 million, marking a 53% reduction since 2022 and boosting overall efficiency.
• Inventory write-offs in Israel: The company cleared C$3.9 million of slow-moving, non-premium stock in 2024 (C$700,000 in Q4), which negatively impacted gross margins and cost of sales.
• Cash and equivalents declined to £0.9 million at year-end from £1.8 million, and the company plans to rely on working capital, credit facilities, and potential new financing to fund operations.

Presentation

[Operator]

Good morning, and welcome to IM Cannabis's fourth quarter and full year 2024 earnings conference call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko, Director of Investor and Public Relations. Anna?

[Anna Taranko, Director of Investor and Public Relations at IM Cannabis Corp.]

Good morning, and thank you, Operator. Joining me for today's call are IM Cannabis Chief Executive Officer Oren Shuster and Chief Financial Officer Uri Birenberg. The earnings and press release that accompanies this call is available on the Investor Relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements, including statements concerning future results of operations, economic conditions, and anticipated courses of action, and are based on assumptions, expectations, estimates, and projections as of the date hereof.

[Anna Taranko, Director of Investor and Public Relations at IM Cannabis Corp.]

This information may involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call.

[Anna Taranko, Director of Investor and Public Relations at IM Cannabis Corp.]

The term non-IFRS Adjusted EBITDA loss, or non-IFRS Adjusted EBITDA, will hereafter be referred to as Adjusted EBITDA loss or Adjusted EBITDA, as applicable. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call, and the company undertakes no obligation to publicly update any forward-looking information or statements or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in Canadian dollars unless otherwise stated. With that, it's my pleasure to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren, please go ahead.

[Oren Shuster, CEO at IM Cannabis Corp.]

Thank you, Anna. Good morning, everyone, and thank you for joining us today. As a medical cannabis company based in Germany and Israel, the April 2024 partial legalization in Germany was a game-changer. Since then, the German market and our sales in Germany have experienced extraordinary growth at a tremendous velocity. My personal 2024 highlights were the continuous improvements we made both strategically and operationally, building a solid lean basis from which to drive sustainable growth in 2025. In 2024, we started to shift our focus from the transition years in 2022 and 2023 towards delivery. At the same time, we continued fine-tuning to maintain our efficiency and agility. This is an ongoing process. It is especially important in the dynamic cannabis market to ensure that we keep our competitive edge.

[Oren Shuster, CEO at IM Cannabis Corp.]

As a company, we had two areas of focus in 2024: one, full integration and active cost management to drive efficiencies; and two, building a strong stable supply chain to support growth in 2025. On an operational level, we continue to lean into active cost management and full integration to drive efficiencies. We reduced our overall operating expenses by CAD 4 million, or 17%, to a total of CAD 18.7 million in 2024. This decrease builds on the 43% decrease we had in 2023, where we spent a total of CAD 22.6 million, coming from CAD 40 million in 2022. Overall, we have managed to reduce our operating expenses by 53% since 2022. The reduction in the operating expenses is most impactful in Q4 of 2024, where we are starting to see initial impact of the saving we initiated during this year.

[Oren Shuster, CEO at IM Cannabis Corp.]

We fully integrated our marketing and supply teams with the goal of building the operational infrastructure and stable supply chain we need to drive growth in Germany in 2025. As a positive upside, we started to see the first results of our efforts in 2024. We imported a total of 11 new strains in Germany in the second half of 2024, with our integrated supply chain for an upside in sales of about 14% in Germany. In total, we added three new suppliers and launched 16 new strains in 2024. When we look at the Adjusted EBITDA after all these measures, our Adjusted EBITDA in Q4 was a gain of CAD 500,000 versus a loss of CAD 4.3 million in Q4 2023, an improvement of almost CAD 5 million. In Q4, we moved into positive Adjusted EBITDA.

[Oren Shuster, CEO at IM Cannabis Corp.]

When we look at the full year, we see a loss of CAD 1.1 million for 2024 versus a CAD 8 million loss in 2023, an improvement of almost CAD 7 million. Moving on to the local level, in Germany, in addition to creating a stronger, fully integrated supply chain, we continue to develop the network of pharmacies we work with directly and worked on building a stronger sales team, consolidating our position as one of the top 10 medical cannabis brands in Israel. Our sales increased by over 183% in 2024 versus 2023, reaching CAD 15.5 million, with supply being the limiting factor, especially in Q4. What I think best sums up the results in Germany is this: Germany made up 40% of IM Cannabis total revenue in the second half of 2024 versus 11% in all of 2023.

[Oren Shuster, CEO at IM Cannabis Corp.]

Looking at these results, it is clear that the strategic shift we made to concentrate our resources on the German market was the right one. In Israel, our team managed to mitigate the impact of the war on our business: the decline in the number of medical cannabis patients, as well as the shift in focus and resources towards the German market. On an operational level in Israel, we launched or relaunched 27 strains across six brands in 2024, maintaining top-line sales. In addition, we moved to a different production facility to reduce our production costs. We expect to see the full effect of this move in 2025. We took a good look at our distribution, outsourcing pharmacy distribution network, and adding distribution partners, further reducing costs and improving service. We spent the better part of 2024 clearing out slow-moving, non-premium stock and all inventory for about CAD 3.9 million.

[Oren Shuster, CEO at IM Cannabis Corp.]

The quality of these products was not one that we, as IM Cannabis, can stand behind. This impacted our cost of sales, gross margin, and gross profit. In Q4, we cleared out final CAD 0.7 million. We do not anticipate a similar scale of write-off in 2025. To sum up 2024, I am delighted with the progress we made internally, both strategically and operationally, while delivering growth. We now have a solid foundation, which is the right size to build on in 2025. You can clearly see the progress we made in 2024 year results. When we look towards 2025, we will be moving our focus from internal to external while working a strategic tightrope, while we need to invest to drive growth in Germany. On the other hand, we do not want to lose the efficiency and agility in our lean structure.

[Oren Shuster, CEO at IM Cannabis Corp.]

I especially look forward to seeing the results of our new solid integrated supply chain in Q1, which is shaping up to be the best quarter in sales we have had to date in Germany. I will now hand the call over to Uri, who will review our fourth quarter and full year 2024 financial results. Uri?

[Uri Birenberg, CFO at IM Cannabis Corp.]

That is one of these quarter milestones that Oren already mentioned. The Adjusted EBITDA in Q4 2024 resulted in a profit of $500,000 compared to an EBITDA loss of $4,300,000 in Q4 2023, which is an improvement of almost $5 million. Our Q4 results were mainly impacted by the following points: our revenue in Q4 increased by 25% versus Q4 2023. This growth was driven mainly by an increase of 280% in the German revenue. We continued with our expense reduction process, which resulted in a decrease in operating expenses of approximately 42% versus Q4 2023. I will now take you through the overview of the Q4 2024 and 2024 full year financial results for the company's operations. Revenues for 2024 and 2023 were $54 million and $48.8 million, respectively, representing an increase of $5.2 million, or 11%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

The increase is mainly attributed to the accelerated growth in Germany, with an increase in revenue of CAD 10 million and decreased revenue in Israel of CAD 4.8 million net. The decrease in Israel is attributed to the Oranim deal cancellation, which resulted in a decrease in revenue of approximately CAD 8.5 million compared to 2023. Excluding the Oranim revenue in 2023, we have an increase of revenue in Israel as well of approximately CAD 3.7 million, or 12%. Revenue for the three months ended December 31, 2024, and 2023 were CAD 13.3 million and CAD 10.7 million, respectively, representing an increase of CAD 2.6 million, or 25%. The increase is mainly attributed to the accelerated growth in Germany, with an increase in revenue of CAD 3.7 million and decreased revenue in Israel of CAD 1.1 million net.

[Uri Birenberg, CFO at IM Cannabis Corp.]

The decrease in Israel is attributed to the Oranim deal cancellation, which resulted in a decrease in revenue of CAD 3.4 million compared to 2023. Excluding the Oranim revenue in Q4 2023, we have an increase of revenue in Israel as well of approximately CAD 2.3 million, or 39%. For the twelve and three months ended December 31, 2024, Germany's share of total revenue has significantly increased compared to the corresponding period in 2023. This increase has had a considerable impact, reflected in higher average price due to the favorable market conditions and growing demand. The cost of revenue for 2024 and 2023 were CAD 45.6 million and CAD 38 million, respectively, representing an increase of CAD 7.6 million, or 20%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

This is mainly due to increasing material costs of approximately CAD 8.1 million, of which clearing old raw materials of approximately CAD 3.9 million and increased inventory sales resulted in an increase of approximately CAD 4 million, which is offset by a reduced in other cost net of approximately CAD 0.5 million. The cost of revenue for the three months ended December 31, 2024, and 2023 were CAD 10.7 million and CAD 9.6 million, respectively, representing an increase of CAD 1.1 million, or 12%. This is mainly due to the increased material cost of approximately CAD 1 million, including clearing old raw material of CAD 0.7 million. Gross profit for 2024 and 2023 were CAD 8.5 million and CAD 9.8 million, respectively, representing a decrease of CAD 1.4 million, or 14%. Gross profit for the three months ended December 31, 2024, and 2023 was CAD 2.7 million and CAD 0.8 million, respectively, representing an increase of CAD 1.8 million, or 238%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Gross profit included losses for realized fair value adjustment on inventory sold of CAD 0 and CAD 1 million for 2024 and 2023, respectively. Gross margin after fair value adjustment for 2024 and 2023, respectively, were 16% versus 20%, and 20% versus 8% for the three months ended December 31, 2024, and 2023. G&A expenses for 2024 and 2023 were CAD 8 million and CAD 11 million, respectively, representing a decrease of CAD 3 million, or 27%. G&A expenses for the three months ended December 31, 2024, and 2023 were CAD 1.2 million and CAD 3.3 million, respectively, representing a decrease of CAD 2.1 million, or 64%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

The G&A expenses are comprised mainly from salaries to employees in the amount of CAD 2.2 million and CAD 0.6 million for the 12 and three months ended December 31, 2024, professional fees in the amount of CAD 2 million and minus CAD 0.3 million for the 12 and three months ended December 31, 2024, depreciation and amortization in the amount of CAD 0.6 million and CAD 0.2 million for the 12 and three months ended December 31, 2024, insurance costs in the amount of CAD 1.3 million and CAD 0.3 million for the 12 and three months ended December 31, 2024, and other expenses in the amount of CAD 1.9 million and CAD 0.4 million for the 12 and three months ended December 31, 2024.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Selling and marketing expenses for 2024 and 2023 were CAD 7.1 million and CAD 10.8 million, respectively, representing a decrease of CAD 3.7 million, or 34%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Selling and marketing expenses for the three months ended December 31, 2024, and 2023 were CAD 1.8 million and CAD 2.8 million, respectively, representing a decrease of CAD 1 million, or 36%. The decrease in selling and marketing expenses for 2024 is mainly attributed to Oranim revoked agreement of approximately CAD 2.1 million and CAD 0.7 million, respectively, in addition to a decrease of CAD 1.6 million and CAD 0.3 million, respectively, in selling and marketing expenses. Total operating expenses for 2024 and 2023 were CAD 18.7 million and CAD 22.6 million. In Q4 2024, the total operating expenses were CAD 3.5 million compared to CAD 6 million in Q4 2023, a decrease of CAD 2.5 million, or 42%. Operating expense ratio for 2024 was 30%, excluding the one-time expense outcome of Oranim deal cancellation versus 46% for 2023, representing an increased efficiency of about 36%.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Operating expenses ratio for the three months ended December 31, 2024, excluding the one-time expense outcome of Oranim deal cancellation was 22% versus 56% for the three months ended December 31, 2023, representing an increased efficiency of about 60%. The efficiency ratio improvement is resulting from decreased operational costs and increased revenue. Adjusted EBITDA loss for 2024 and 2023 was CAD 1.1 million compared with CAD 8 million, representing a decrease of 87%. Adjusted EBITDA profit in Q4 2024 was CAD 0.5 million compared to an EBITDA loss of CAD 4.3 million in Q4 2023. Net loss for 2024 was CAD 11.8 million compared to CAD 10.2 million for 2023. Net loss in Q4 2024 was CAD 1.2 million compared to CAD 3.5 million in Q4 2023. Diluted loss per share for 2024 was CAD 4.51 compared to a loss of CAD 4.45 per share in the same period for year 2023.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Diluted loss per share for Q4 2024 was $0.32 compared to a loss of $1.47 per share in Q4 2023. As of the balance sheet, cash and cash equivalent as of December 31, 2024, were CAD 0.9 million compared to CAD 1.8 million on December 31, 2023. Total assets as of December 31, 2024, were CAD 39.2 million compared to CAD 48.8 million on December 31, 2023, a decrease of CAD 9.6 million, or 19.7%. The decrease is mainly attributed to the Oranim agreement cancellation of CAD 9.5 million, of which mainly attributed to goodwill CAD 3.5 million, intangible asset CAD 1.4 million, inventory CAD 0.8 million, trade receivables CAD 1.3 million, property, plant, and equipment CAD 0.8 million, and reduction of cash and cash equivalent of CAD 0.3 million.

[Uri Birenberg, CFO at IM Cannabis Corp.]

In addition to the Oranim revocation agreement effect, there is a total asset decrease of CAD 0.1 million, mainly due to the increase of CAD 7.5 million in trade receivable, offset by CAD 5.9 million reduction in inventory, and the reduction of CAD 1.1 million in intangible assets. Total liabilities as of December 31, 2024, were CAD 36 million compared to CAD 35.1 million on December 31, 2023, an increase of CAD 0.9 million, or 3%. The Oranim agreement cancellation effect is a decrease of CAD 6.8 million, of which mainly attributed to put option liability CAD 2 million, purchase consideration payable CAD 2.2 million, trade payables CAD 1.6 million, lease liabilities CAD 0.4 million, and a decrease of CAD 0.3 million in deferred tax liability.

[Uri Birenberg, CFO at IM Cannabis Corp.]

In addition to the Oranim revocation agreement effect, there is a total liability increase of CAD 7.7 million, mainly due to an increase of CAD 3.5 million in trade payables and an increase of CAD 3.3 million in warrants and convertible debt. The company is planning to finance its operation from its existing and future working capital resources, as well as from available credit facilities, and will continue to evaluate additional sources of capital and financing as needed. I would like now to turn the call back to Oren for closing remarks. Oren?

[Oren Shuster, CEO at IM Cannabis Corp.]

Thank you, Uri. To sum up 2024, while I'm very proud of the growth IM Cannabis delivered in Germany, I'm delighted with the progress we made internally, both strategically and operationally.

[Oren Shuster, CEO at IM Cannabis Corp.]

In Q4, with our positive Adjusted EBITDA, we are starting to see the initial impact of the saving we initiated during 2024 through our active cost management and full integration. This gives us a very strong foundation leading into 2025, where we already see that Q1 is shaping up to be the best quarter in sales we have had to date in Germany. I will now hand the call over to the operator to begin our question and answer session. Operator?

[Operator]

Thank you. In order to ask a question, please raise your hand and use your mobile or desktop application and wait for your name to be announced. I repeat, in order to ask a question, please raise your hand using your mobile or desktop application and wait for your name to be announced. Aaron Gray, please go ahead.

[Operator]

Thank you very much for the questions today.

[Operator]

First question for me, just wanted to touch on Germany. Great to hear that 1Q is off to a great start. If we just touch back on 4Q, and again, this is specifically on Germany, it does look like it was a little bit, you know, softer. Obviously, you've had tremendous growth in 2Q and 3Q for Germany. Looks like some of that growth stopped and still hit about, you know, $5 million from what I'm seeing here. But he talked about were there dynamics specifically, you know, in the quarter that slowed some of that growth that seems to have come back in 1Q. Or just some of the dynamics that's going on within the German market there that might have led to some.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Hi, Aaron. Okay, thank you for the question, Aaron.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Like you said, we started with a very strong growth in Q2 and Q3. In Q4, we had some delays, but I think that I said that it was just a delay, and Q1 looks very good, and it's not something that is part of the ongoing. I think that it's part of building the supply chain. It's a long process, and I think that the target was to be very stable with the supply in 2025, and we are going into 2025 with the much stronger supply chain, and I believe that we will see it also in the quantities in 2025.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, thanks. Can you comment on any changes you're seeing in the competitive dynamic for Germany?

[Uri Birenberg, CFO at IM Cannabis Corp.]

Obviously, there's a lot of operators internationally that are putting a lot of focus on the German market, so changing competition, whether it be pricing or otherwise, that you're starting to see?

[Uri Birenberg, CFO at IM Cannabis Corp.]

The German market is very dynamic. I think that what we see is that the market is changing from week to week. There is definitely a competition in the market. It's still, we see more or less the same leading competitors. This is what we feel right now. The German market value products are very successful in the German market, and it's very clear. I don't foresee very big change. The market will be competitive. It's part of our plans. I believe that there will be a price compression. There is a price compression, and it's part of what we took in our plan from the beginning.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, I appreciate that color.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Just kind of picking back off of that, with the price compression, how should we think about the margin profile? Still had 20% gross margin for the quarter. That EBITDA, you know, positive there. How should we think about the margin progression for the year as we think about, you know, potential growth, but also some pricing pressure?

[Uri Birenberg, CFO at IM Cannabis Corp.]

It is difficult. It is very difficult to know how the market will develop because also there have been some political changes in Germany. I think that we do not think that we will go down with the margins in our estimates. We even think that it might be better than it is now.

[Uri Birenberg, CFO at IM Cannabis Corp.]

If I may add, you cannot take Q4 as a reference for future expectations regarding gross margin simply because of the one-time event related to inventory over the year.

[Uri Birenberg, CFO at IM Cannabis Corp.]

We cleaned all our old inventory, and we are set for new inventory to sell, and there is a big demand in Germany, also in Israel. I'm expecting it to be better than what you see in 2024 for sure. To say exactly how much, it's a little bit complicated, but 20% that you mentioned is not the levels that we expect. It's Uri Birenberg, the CFO.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, that's helpful. Last question for me, just on Israel. Seems to have stabilized a bit there. You know, I had seen a little bit of softness. Are you feeling comfortable with that market now? I know there's been a lot of shakeout between competitors, you know, fewer products coming from Canadian LP. Just commenting quickly on the broader, you know, Israeli market and how you're expecting for that to evolve in 2025.

[Uri Birenberg, CFO at IM Cannabis Corp.]

As of now, we do not foresee any significant growth in the Israeli market. We think that it will be more or less stable unless we see some regulations change. The focus on growth for us is mainly in Germany.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, all right. Thanks very much. I will jump back into the queue.

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, thank you. Thank you very much, Aaron.

[Anna Taranko, Director of Investor and Public Relations at IM Cannabis Corp.]

Thank you. In order to ask a question, please raise your hand using your mobile or desktop application and wait for your name to be announced. Are there any further questions?

[Uri Birenberg, CFO at IM Cannabis Corp.]

Okay, thank you, Operator, and thank you all for joining our call today.

Participants

Executives

• Oren Shuster, CEO
• Anna Taranko, Director of Investor and Public Relations
• Uri Birenberg, CFO

Analysts

• Analyst